CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells $50,819.16 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report) COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at $350,516.46. This represents a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

CRISPR Therapeutics Trading Up 0.3 %

Shares of NASDAQ CRSP opened at $42.12 on Friday. The firm has a market cap of $3.61 billion, a PE ratio of -9.64 and a beta of 1.77. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $75.91. The company has a fifty day moving average price of $43.06 and a 200 day moving average price of $45.58.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on CRSP. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Citigroup decreased their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday, February 18th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group decreased their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $73.11.

Check Out Our Latest Report on CRISPR Therapeutics

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Wood Tarver Financial Group LLC bought a new stake in CRISPR Therapeutics during the 4th quarter worth about $30,000. Ameriflex Group Inc. bought a new stake in CRISPR Therapeutics during the 4th quarter worth about $36,000. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP raised its holdings in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at about $40,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Insider Buying and Selling by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.